293 / 320
697
OATP/SLCO superfamily, new nomenclature and molecular/
functional properties. Pflugers Arch 2004; 447:653–665.
63. Ward PD, La D, McDuffie JE. In: Gowder S, editor. Renal
transporters and biomarkers in safety assessment, new
insights into toxicity and drug testing. InTech; 2013. ISBN:
978-953-51-0946-4,.
http://www.intechopen.com/books/
new-insights-into-toxicity-and-drug-testing/renal-trans-
porters-and-biomarkers-in-safety-assessment.
64. Nuñez MJ, Martin-Carbonero L, Moreno V, Valencia E, Garcia-
Samaniego J, Gonzalez-Castillo J, et al. Impact of antiretroviral
treatment-related toxicities on hospital admissions in HIV-
infected patients. AIDS Res Hum Retroviruses 2006; 22:825–
829.
65. Nuñez M, Lana R, Mendoza J, Mart
́
ın-Carbonero L, Soriano
V. Risk factors for severe hepatic injury following the intro-
duction of HAART. J Acquir Immune Def Syndr 2001; 27:
426–431.
66. Kaplowitz N. Drug-induced liver disorders: implications for
drug development and regulation. Drug Saf 2001; 24:483-
490.
67. Zimmerman H. Drug-induced liver disease. In: Schiff E, editor.
Schiff’s Diseases of the Liver, Vol. 8. Philadelphia: Lippincott-
Raven Publishers; 1999. pp. 973 – 1064.
68. Bissell D, Gores G, Laskin D, Hoofnagle J. Drug-induced liver
injury: mechanisms and test systems. Hepatology 2001;
33:1009–1013.
69. Nathwani R, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis
2006; 10:207–217.
70. Haas D, Bartlett J, Andersen J, Sanne I, Wilkinson G, Hinkle J,
et al. Pharmacogenetics of nevirapine-associated hepatotoxi-
city: an adult ACTG collaboration. Clin Infect Dis 2006;
43:783–786.
71. Ritchie M, Haas D, Motsinger A, Donahue JP, Erdem H,
Raffanti S, et al. Drug transporter and metabolizing enzyme
gene variants and NNRTI hepatotoxicity. Clin Infect Dis 2006;
43:779–782.
72. Leist M, Gantner F, Kunstle G, Wendel A. Cytokine-mediated
hepatic apoptosis. Rev Physiol Biochem Pharmacol 1998;
133:109–155.
73. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;
38 (suppl 2):44–48.
74. Dubé MP, Sprecher D, Henry WH, Aberg JA, Torriant FJ, Hodis
HN, Schouten J, Levin J, Myers G, Zackin R, Nevin T, Currier JS
for the Adult AIDS Clinical Trial Group Cardiovascular Disease
Focus Group. Clinical Infection Disease 2000; 31: 1216-
1224.
75. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós
F, et al PREDIMED Study Investigators. Primary prevention of
cardiovascular disease with a Mediterranean diet. N Engl J
Med. 2013 Apr 4;368(14):1279-90).
76. Micromedex® Healthcare Series y Lexi-comp® consultada el [
04 de Mayo del 2016].
77. Jean C. Yombia, b, Anton Pozniakb , Marta Boffitob , Rachael
Jonesb , Saye Khooc , Jeremy Levyd et al. Antiretrovirals and the
kidney in current clinical practice: renal pharmacokinetics,
alterations of renal function and renal toxicity. AIDS 2014,
28:621–632.
78. Sax PE, Whol D, Yin MT, Post F, DeJesus E, Saag M et al.
Tenofovir alafenamide versus tenofovir disoproxil fumarate,
coformulated with elvitegravir, cobicistat, and emtricitabine,
for initial treatment of HIV-1 infection:two randomised,
double-blind, Phase 3, non-inferiority trials. Lancet. 2015
385(9987):2,606-2,615.
79. Rojas J, Blanco JL, Lonca M, et al. Dolutegravir Monotherapy
in HIV-infected Patients with Sustained Viral Suppression:
A 24-week Pilot Study. 15th European AIDS Conference.
October 21-24, 2015. Barcelona, Spain. Abstract 1108.
80. Injectable regimen for HIV maintenance therapy. Press
release. November 3, 2015. Janssen Sciences Ireland UC. First
Investigational All Injectable Long Acting HIV Combination
Regimen Study Results at 32 Weeks Announced. Press release.
November 3, 2015.
81. Guido van den Berk, Josephine Oryszczyn, Willem Blok,
Nar da van der Meche, Rosa Regez, Daoud Ait Moha, et al.
Unexpectedly High Rate of Intolerance for Dolutegravir in Real
Life Setting. CROI 2016, abstract 948.
82. Markowitz M et al. ÉCLAIR: Phase 2A Safety and PK Study
of Cabotegravir LA in HIV-Uninfected Men. Conference on
Retroviruses and Opportunistic Infections, Boston, CROI
2016, abstract 10.
[FARMACOLOGÍA DE LOS ANTIRETROVIRALES - Q.F. Fernando Bernal]